Sun-Ranbaxy Deal Valuation Reasonable: PwC
  • Prabha Hedge
  • Apr 07 2014

April 7: Talking about the mega-pharma deal between Sun Pharma and Ranbaxy, Sujay Shetty, ED, Pharma Lifesiences, PwC, says, “The deal spells out a huge relief for Daiichi Sankyo.” D.G. Shah, Secretary General, Indian Pharmaceutical Alliance, also adds, “The deal sets a positive trend in terms of consolidation within the pharma industry.” Harsha Subramaniam also discusses the implications of the deal with Vikas Dandekar, India Bureau Chief, Elsevier Business Intelligence.